Abiopharma

🔍 Parker Craig C (Executive)

Company: Surrozen, Inc./DE (SRZN)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Acquired 12,500 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: M | equity_swap_involved: false | shares_owned_after: 21,077.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 4,524 shares of Common Stock at $33.3328 per share (Direct)
  Date: 2026-05-04 | Code: S | equity_swap_involved: false | shares_owned_after: 16,553.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 12,500 shares of Restricted Stock Unit (Derivative)
  Date: 2026-05-01 | Code: M | equity_swap_involved: false | shares_owned_after: 12,500.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3

Footnotes:

• F1: Each restricted stock unit, or RSU, represents a contingent right to receive one share of the Issuer's common stock.
• F2: The shares were sold to cover withholding taxes upon vesting of RSUs in transactions that were initiated by the Issuer on the reporting person's behalf. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.04 to $33.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
• F3: These RSUs vest in two equal installments on May 1, 2026 and May 1, 2027.